anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Time restricted eating (TRE) has become a popular weight loss regimen. The sudden rise in popularity of TRE is mostly likely due to is its sheer simplicity, and the fact that it does not require individuals to count calories in order to lose weight. Participants are simply asked to consume all food within a specified time frame and fast with energy free beverages for the remaining hours of the day. Evidence shows that when people with obesity limit their eating window to 6 to 8 hours per day, they naturally reduce energy intake by 350-500 calories. From a clinical standpoint, these findings are paramount. One of the main reasons for subject attrition with traditional dieting, i.e. daily calorie restriction (CR), is frustration with having to count calories every day. TRE regimens are able to side-step this requirement by allowing participants to simply "watch the clock" instead of monitoring calories, while still producing significant weight loss and metabolic health improvements. This feature of TRE has the potential to improve long-term adherence to the diet, and in turn produce lasting weight control in adults with obesity.

Accordingly, we conducted a one-year, randomized, controlled trial to compare the effects of late TRE (eating all food between 12:00 pm to 8:00 pm, without calorie counting), versus CR (25% energy restriction daily), and a control group eating over a period of 10 or more hours, on body weight and metabolic risk factors in a diverse group of American adults with obesity. We hypothesized that the TRE group would achieve greater weight loss, and experience more pronounced improvements in insulin sensitivity during the 6-month weight loss phase, compared to CR and control participants. We also hypothesized that the TRE group would better maintain their weight loss and sustain their improvements in insulin sensitivity during the 6-month weight maintenance phase, when compared to the CR and control participants.
The invention relates to a traditional Chinese medicine composition for treating leukopenia caused by cancer chemotherapy and a preparation method thereof, belonging to the technical field of traditional Chinese medicine preparations. The technical scheme is that the traditional Chinese medicine is prepared from the following raw materials in parts by weight: 15-90 parts of astragalus membranaceus, 10-70 parts of ox horn cheek, 15-60 parts of caulis spatholobi, 15-60 parts of hairyvein agrimony and 10-50 parts of Chinese pine cone. In the formula, astragalus root is monarch and ox horn cheek are ministers, caulis spatholobi and hairyvein agrimony are used as assistants, and lignum pini koraiensis is used as a minister, so that the traditional Chinese medicine theory for treating consumptive disease is met. Another object of the present invention is to provide a method for preparing the Chinese medicinal composition of the present invention. The Chinese medicinal composition of the invention can also be added with pharmaceutically acceptable carriers, and the carriers comprise but are not limited to excipients, flavoring agents, fillers, binders, wetting agents, disintegrating agents and lubricants. The clinical embodiment shows that the traditional Chinese medicine preparation is a medicine which has reliable curative effect, is safe and effective for treating the leucopenia caused by cancer chemotherapy, and is worthy of further popularization.
Certain exemplary embodiments can provide a method. The method can comprise causing a first user interface to be automatically rendered on a device via an App. The first user interface can comprise health instructions. The health instructions can be rendered responsive to a communication from a server to the App. The communication from the server comprises the health instructions. The health instructions can be determined via the server based upon an Artificial Intelligence algorithm.
An AB single-case experimental design will be used. An RCT would be inappropriate since the befriending intervention is known to improve wellbeing. As such participants will have data collected in a pre- and post-intervention phase, for a maximum of 13 time points. This approach has been identified by What Works Clearinghouse as an acceptable empirical design to include in evidence based practice reviews (Kratchowill et al., 2010).
Peri-menopause was defined as the presence of menses within the past 3 months with a decrease in cycle predictability in the year preceding examination or 3-11 months of amenorrhea. To investigate the association between serum FSH and cholesterol levels independent of E2, we further selected peri-menopausal subjects with the presence of menses within the past 3 months with a decrease in cycle predictability in the year preceding examination because their E2 levels have been reported to be similar to those in pre-menopause.
Neonatal brain inflammation produced by intraperitoneal (i.p.) injection of lipopolysaccharide (LPS) results in long-lasting brain dopaminergic injury and motor disturbances in adult rats. The goal of the present work is to investigate the effect of neonatal systemic LPS exposure (1 or 2 mg/kg, i.p. injection in postnatal day 5, P5, male rats)-induced dopaminergic injury to examine methamphetamine (METH)-induced behavioral sensitization as an indicator of drug addiction. On P70, subjects underwent a treatment schedule of 5 once daily subcutaneous (s.c.) administrations of METH (0.5 mg/kg) (P70-P74) to induce behavioral sensitization. Ninety-six hours following the 5th treatment of METH (P78), the rats received one dose of 0.5 mg/kg METH (s.c.) to reintroduce behavioral sensitization. Hyperlocomotion is a critical index caused by drug abuse, and METH administration has been shown to produce remarkable locomotor-enhancing effects. Therefore, a random forest model was used as the detector to extract the feature interaction patterns among the collected high-dimensional locomotor data. Our approaches identified neonatal systemic LPS exposure dose and METH-treated dates as features significantly associated with METH-induced behavioral sensitization, reinstated behavioral sensitization, and perinatal inflammation in this experimental model of drug addiction. Overall, the analysis suggests that the implementation of machine learning strategies is sensitive enough to detect interaction patterns in locomotor activity. Neonatal LPS exposure also enhanced METH-induced reduction of dopamine transporter expression and [3H]dopamine uptake, reduced mitochondrial complex I activity, and elevated interleukin-1β and cyclooxygenase-2 concentrations in the P78 rat striatum. These results indicate that neonatal systemic LPS exposure produces a persistent dopaminergic lesion leading to a long-lasting change in the brain reward system as indicated by the enhanced METH-induced behavioral sensitization and reinstated behavioral sensitization later in life. These findings indicate that early-life brain inflammation may enhance susceptibility to drug addiction development later in life, which provides new insights for developing potential therapeutic treatments for drug addiction.
Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
Hepatocyte plays a principal role in preserving integrity of the liver homeostasis. Our recent study demonstrated that Kindlin-2, a focal adhesion protein that activates integrins and regulates cell-extracellular matrix interactions, plays an important role in regulation of liver homeostasis by inhibiting inflammation pathway; however, the molecular mechanism of how Kindlin-2 KO activates inflammation is unknown. Here, we show that Kindlin-2 loss largely downregulates the antioxidant glutathione-S-transferase P1 in hepatocytes by promoting its ubiquitination and degradation via a mechanism involving protein-protein interaction. This causes overproduction of intracellular reactive oxygen species and excessive oxidative stress in hepatocytes. Kindlin-2 loss upregulates osteopontin in hepatocytes partially because of upregulation of reactive oxygen species and consequently stimulates overproduction of inflammatory cytokines and infiltration in liver. The molecular and histological deteriorations caused by Kindlin-2 deficiency are markedly reversed by systemic administration of an antioxidant N-acetylcysteine in mice. Taken together, Kindlin-2 plays a pivotal role in preserving integrity of liver function.
The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
PURPOSE: A pharmaceutical composition for preventing or treating enterohemorrhagic E. colibacillosis is provided to show excellent antibacterial activity against enterohemorrhagic E.coli O157:H7 using a Patrinia scabiosaefolia extract. CONSTITUTION: A pharmaceutical composition for preventing or treating enterohemorrhagic E. colibacillosis contains a Patrinia scabiosaefolia extract as an active ingredient. The extract is prepared from Patrinia scabiosaefolia using water, C1-C4 alcohol, or a mixture thereof. The C1-C4 alcohol is methanol or ethanol. The extract is an ethyl acetate fraction of Patrinia scabiosaefolia. [Reference numerals] (AA) Amphicilin; (BB) Methyl acetate fraction of Patrinia scabiosaefolia
Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
Moderately elevated albuminuria (30-300 mg/g) is a marker of renal dysfunction and a risk factor of cardiovascular disease. Additionally, several recent studies have reported a relationship between moderately elevated albuminuria and triglyceride (TG) levels. Therefore, we aimed to evaluate the relationship between the urine albumin-to-creatinine ratio (UACR) and total cholesterol (TC), TG, and high-density lipoprotein C (HDL-C) levels. We analyzed data from 19,340 patients from the 2011-2014 and 2019-2020 from the Korea National Health and Nutrition Examination Surveys. Multivariate linear regression analysis showed that the UACR was positively associated with TC and TG levels and negatively associated with HDL-C levels in both Korean women and men. These results were reanalyzed according to the degree of proteinuria (normal, moderately elevated albuminuria, and severely elevated albuminuria (≥ 300 mg/g)). We found a positive relationship between UACR and TC and TG levels, but a negative association with HDL-C levels, except for TC (moderately elevated albuminuria) and HDL-C (moderately elevated albuminuria) in Korean men and TC (severely elevated albuminuria), TG (severely elevated albuminuria), and HDL-C (normal range albuminuria) in Korean women. The correlation between albuminuria and lipid profiles became more evident as albuminuria shift from normal to the severely elevated albuminuria. Thus our multivariate linear regression analysis showed that lipid profiles (TG, TC, and HDL-C levels) were associated with the UACR.
Title cpds. of formula (I) (where R is H or an acid residue), which are anabolics with a particularly favourable dissociation of the desired anabolic activity from undesired androgenic side-effects, are prepd. by methylating corresp. 15 alpha, 16 alpha-methylene-5 alpha-androst-1-en, in a conventional manner with a methyl Mg halide in the presence of cuprous chloride and opt. saponifying an ester gp. in the product or esterifying a free hydroxy gp.
1. A polypeptide for increasing the efficiency of gene transfer into target cells with a retrovirus, represented by SEQ. ID 13 of the Sequence Listing, a functional equivalent thereof, obtained by deletion, exchange, insertion and/or amino acid residue additions. 2. A polypeptide for increasing the efficiency of gene transfer into target cells with a retrovirus, represented by SEQ. ID 30 of the Sequence Listing, a functional equivalent thereof, obtained by deletion, exchange, insertion and/or amino acid residue additions. 3. A polypeptide for increasing the efficiency of gene transfer into target cells with a retrovirus, represented by SEQ. ID 5 of the Sequence Listing, a functional equivalent thereof, obtained by deletion, exchange, insertion and/or amino acid residue additions. 4. A gene encoding the polypeptide according to claim 1. 5. A gene encoding the polypeptide according to claim 2. 6. A gene encoding the polypeptide according to claim 2. 7. A gene according to claim 4 which is represented by SEQ.ID No. 17 of the Sequence Listing, or a gene hybridizable thereto under stringent conditions and encoding a polypeptide which improves the efficiency of gene transfer into target cells with a retrovirus. 8. A gene according to claim 5 which is represented by SEQ.ID No. 33 of the Sequence Listing, or a gene hybridizable thereto under stringent conditions and encoding a polypeptide which improves the efficiency of gene transfer into target cells with a retrovirus. 9. A gene according to claim 5 which is represented by SEQ.ID No. 26 of the Sequence Listing, or a gene hybridizable thereto under stringent conditions and encoding a polypeptide which improves the efficiency of gene transfer into target cells with a retrovirus.
Ten SJS patients with dry eye and 10 non-autoimmune dry eye patients are recruited in this study. Twenty to forty mL of peripheral venous blood is drawn and the serum is separated. The serum is diluted with Balanced Salt Solution (BSS) to provide 20% ASE. The levels of EFG, TGF-β1, TGF-β2, and fibronectin in 20% ASE are quantitated by enzyme-linked immunosorbent assay (ELISA) method and are compared between the two groups of samples. To study the stability of these serum factors under storage conditions used in clinical settings, 20% ASE are stored at different temperature and time i.e., at 4 ํC for 1 week and 1 month, and at -20 ํC for 1, 3 and 6 month. Their levels are then measured following each storage condition.
Only the pre-test will be applied to the caregivers of cancer patients in the Medical Oncology clinic in the control group. After the caregiver introduction form and Piper fatigue scale application, no breathing exercises will be performed. Individuals will continue their daily lives. Four weeks later the Piper fatigue scale will be administered again. After the Piper fatigue scale is applied, pranayama breathing exercise training will be given to all control group patients and they will be applied for 2 sessions.
AIMS: Post-ovariectomy (OVX) changes in hormones induce obesity and white adipose tissue (WAT) inflammation. Increased energy expenditure via WAT browning is a novel therapeutic strategy for treating obesity. Naringenin (NAR) reduces inflammation and lipogenesis in obesity and attenuates estrogen deficiency-associated metabolic disorders; however, its role in WAT browning remains unclear.
MATERIALS AND METHODS: We investigated NAR ability to inhibit estrogen deficiency-associated obesity in vivo using a rat model and in vitro using 3T3-L1 adipocytes.
KEY FINDINGS: NAR significantly decreased the body weight and WAT mass of rats. O2 consumption, CO2 production, and energy expenditure were significantly lower in the OVX group than in the sham group, but NAR treatment reversed these effects of OVX. NAR treatment markedly improved glucose intolerance and lipid profiles as well as leptin, adiponectin, and irisin levels. NAR upregulated markers of browning and mitochondrial biogenesis in inguinal WAT. Moreover, it enhanced markers of mitochondrial fusion and inhibited fission via activating the AMP-activated protein kinase pathway. Similar results were observed in 3T3-L1 adipocytes. Moreover, NAR-induced mitochondrial biogenesis and fusion were suppressed by dorsomorphin (an AMP-activated protein kinase inhibitor).
SIGNIFICANCE: NAR alleviates obesity and metabolic dysfunction through the induction of WAT browning achieved via the modulation of AMP-activated protein kinase-regulated mitochondrial dynamics in WATs. NAR supplementation may therefore represent a potential intervention for preventing postmenopausal adipose tissue dysregulation.
Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
Before the application of nursing interventions ( Intamuscular , Intravenous , Subcutaneous Injection) to the patients, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. During the nursing intervention, the patients watched 3D videos with relaxation effect with virtual glasses. After the application, the patients' physiological parameters (fever, pulse, blood pressure, respiration and oxygen saturation ), pain levels with VAS and anxiety levels with State -Trait Anxiety Scale were evaluated. Whichever nursing intervention was necessary ( Intamuscular , Intravenous , Subcutaneous Injection), that application was performed on the patients . No unnecessary procedure was performed.
This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
This is prospective, randomized, multicenter, superiority study. 8 top centers in China was chosen. Subject which has peripheral lung lesions (PLLs) detected by chest CT scan, requires biopsy diagnosis, and meets all inclusion and exclusion criteria, will be included in this trial. Firstly physician determines the lesion biopsied, then the subject will be randomized to experimental or control group. The experimental group is treated with ENB guided transbronchial lung biopsy (TBLB)(ENB-TBLB): Under ENB guidance, the location sensor reaches the edge of the lesion, and X-ray is used for actual distance confirmation, if physician determines the distance is enough for biopsy, TBLB will be conducted. The control group will be treated with TBLB using X-ray guidance.
The invention provides construction of a target-to-cell endoplasmic reticulum nano drug delivery system, which is realized by modifying Pardaxin polypeptide on the surface of a liposome. The Pardaxin is a polypeptide which contains 33 amino acid residues and has a membrane penetrating effect in an amphiphilic cation alpha helical structure. The constructed nano drug-carrying system can be applied to preparing antiviral, antitumor and other drugs taking endoplasmic reticulum as a target. The nano drug-loading system can load water-soluble and fat-soluble drugs and transfer the drugs to endoplasmic reticulum parts, thereby enhancing the therapeutic effect of the drugs and reducing toxic and side effects. The nano-carrier is not limited to liposome, but also can be solid lipid nanoparticles, nano-emulsion, polymer micelle, inorganic nano-material and the like. The novel endoplasmic reticulum targeted nano-carrier constructed by the invention can obviously improve the concentration of the medicine taking the endoplasmic reticulum as a target at the action target part, and provides a new way for the curative effect exertion of the medicines.
As many as 20 percent of women suffer from snoring and poor sleep quality while pregnant. The purpose of this study is to determine whether sleep can be improved in pregnant women who snore by means of a midline traction oral appliance (OA) that opens the airway. This is an interventional study to objectively evaluate OA therapy on breathing during sleep as well as its effect on sleep quality. Pregnant women from all trimesters will be recruited. Each subject is expected to participate in the study for at least five (5) consecutive weeks. Home sleep recordings will be collected at three time points: T0 - Baseline prior to OA use for two consecutive nights; T1- first two consecutive nights wearing the OA; T2 - for two consecutive nights after 4 weeks of appliance use. In addition to the sleep studies performed at each of these time points, subjects will also complete several brief surveys. All participants will be given the opportunity to use their OAs after the 4 week period, and have their sleep recorded at 8 week intervals through the remainder of their pregnancies. Participants will get to keep and use their OAs after the study.

Pregnant women who snore (or otherwise have poor sleep), may qualify to participate in this study. Those who do not want to wear an oral appliance, but are interested in learning about sleep quality while pregnant, may also qualify to participate as a control subject.
PURPOSE:To obtain an antibacterial agent having inhibitory power on a wide range of bacteria and safety to human body, comprising a culture product of Lactobacillus jugurti strain 4811 of lactic acid bacteria as an active ingredient. CONSTITUTION:Lactobacillus jugurti strain 4811 (FERM P-9145) of lactic acid bacteria separated from dairy product is subjected to stationary culture in a medium containing preferably skim milk, etc., under aerobic condition. The cell is removed from the culture solution by centrifugal separation method, ethanol is added to the solution, which is allowed to stand and centrifuged to remove ethanol. Then the solution is dissolved in a phosphoric acid buffer solution, purified and separated to give a saccharide-containing polypeptide having 3,400mol.wt. The polypeptide as an active ingredient is pharmaceutically manufactured to give an antibacterial agent. A food having excellent shelf stability is obtained by using the antibacterial agent to a food.